Figure 13.

Relative cell viability of SH-SY5Y cell line measured by the MTT reduction after 24 h incubation. (A) Represents NLC safety test with the treatment of free RAS, blank CT25 and RAS-loaded CT25 (0.25–10 µM). (B) Represents differences in the cell viability of treatment with free RAS, RAS-MAP, blank CT25, RAS-loaded CT25, MAP, RAS-MAP-loaded CT25 (0.25–10 µM). (C) Represents co-administration of RAS and RAS-MAP with blank CT25 (1–10 µM). (D) Represents the data obtained from the encapsulation of Lys(N₃)-MAP and co-encapsulation of RAS and Lys(N₃)-MAP in the NLC compared with peptide conjugate. Results are expressed as means ± SD (n = 4). Statistical analysis between the groups was performed using two-way ANOVA with Tukey’s multiple comparisons test (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).